High-mobility group box 1 is involved in neuromyelitis optica pathogensesis and could be a therapeutic target.
| Project/Area Number |
24790873
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
UZAWA Akiyuki 千葉大学, 医学部附属病院, 助教 (10533317)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 視神経脊髄炎 / HMGB1 / サイトカイン / 多発性硬化症 / 実験的自己免疫性脳脊髄炎 / 自己免疫疾患 / モノクローナル抗体 / 血液脳関門 / モデル動物 / GFAP |
|---|
| Research Abstract |
Cerebrospinal fluid (CSF) high-mobility group box 1 (HMGB1) levels in neuromyelitis optica (NMO) patients were significantly higher than those in multiple sclerosis (MS) and controls patients. In addition, CSF HMGB1 levels significantly correlated with CSF cell counts, protein levels, interleukin-6 levels, glial fibrillary acidic protein levels and CSF/serum albumin ratio in NMO. Administration of an anti-HMGB1 monoclonal antibody ameliorated the clinical and pathological severity of experimental autoimmune encephalomyelitis (EAE) and attenuated serum interleukin-17 up-regulation. HMGB1 could play a key role in central nervous system inflammation in NMO patients and EAE. HMGB1 could be a novel therapeutic strategy for NMO.
|
Report
(3 results)
Research Products
(30 results)
